scholarly journals Connexin-Based Channels and RhoA/ROCK Pathway in Angiotensin II-Induced Kidney Damage

2020 ◽  
Author(s):  
Gonzalo I. Gómez ◽  
Victoria Velarde ◽  
Juan C. Sáez
Keyword(s):  
Angiotensin Ii ◽  
Kidney Damage

scholarly journals Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II–dependent kidney damage

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Humberto Reyes-Pardo ◽  
Rocío Bautista ◽  
Hilda Vargas-Robles ◽  
Amelia Rios ◽  
Daniel Sánchez ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Rat Model ◽  
Kidney Damage ◽  
Sodium Glucose Cotransporter

scholarly journals Angiotensin II and transforming growth factor β affect cardiovascular and renal disease in patients with type 2 diabetes mellitus: benefits of dpp-4 inhibitors treatment

2019 ◽  
Vol 16 (3) ◽  
pp. 55-61
Author(s):  
Teona A. Shvangiradze ◽  
Irina Z. Bondarenko ◽  
Ekaterina A. Troshina ◽  
Marina V. Shestakova ◽  
Larisa V. Nikankina ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Angiotensin Ii ◽  
Growth Factor ◽  
Glucose Metabolism ◽  
Transforming Growth Factor ◽  
Kidney Damage ◽  
Ang Ii ◽  
Increased Risk ◽  
Wide Range

BACKGROUND: Diabetes mellitus type 2 (T2DM) is associated with impaired glucose metabolism and peripheral insulin resistance, which is accompanied by an high risk of cardiovascular disease (CVD) and nephropathy. Metabolic syndrome and T2DM are accompanied by renin-angiotensin system (RAS) activation, which is also associated with increased risk of CVD and kidney damage. Obesity lead to a wide range of pathophysiological changes, that stimulate cardiac fibrosis, and various fibrosis processes initiation, including activation of transforming growth factor (TGF-). AIMS: To determine activity of angiotensin II (Ang II) and TGF- in patients with obesity and T2DM and their association with heart and kidney damage. MATERIALS AND METHODS: Ang II and TGF- were identified in the peripheral blood of 66 obese patients aged 48-65 years. The first group included 21 patients with coronary heart disease (CHD) and T2DM; The second group included 22 patients with T2DM and excluded CHD; The third group 20 patients with normal glucose metabolism and excluded CHD. RESULTS: The values of TGF- in the 1st group (patients with CHD) were statistically lower than in the group of metabolically healthy obesity (p=0.021). Patients who received DPP-4 inhibitors had a lower Ang II level compared to patients with other hypoglycemic therapy (p=0.005). TGF- positively correlated with glomerular filtration rate (eGFR) in all patients (r=-0.414, p=0.006). TGF- negatively correlated with the degree of internal carotid artery stenosis in patients of the 2nd group (r=-0.42, p=0.09) and LDL-cholesterol in all patients (r=-0.426, p=0.038). CONCLUSIONS: TGF- negatively correlated with the factors that contribute to CVD progression. TGF- correlated with pathological angiogenesis and changes in normal cardiac geometry in obesity, T2DM and CHD. DPP-4 inhibitors can improve the cardiovascular prognosis in this group of patients by affecting Ang II level. Low levels of TGF- were associated with higher cardiovascular risk and were commonly found in patients with more severe nephropathy.

scholarly journals Angiotensin II receptors blockers in the treatment of patients with cardiorenal syndrome

2015 ◽  
Vol 96 (6) ◽  
pp. 1010-1014
Author(s):  
A A Nasybullina ◽  
O V Bulashova ◽  
E V Khazova ◽  
V M Gazizyanova ◽  
M I Malkova
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Left Ventricular ◽  
Kidney Damage ◽  
Angiotensin Ii Receptor Blockers ◽  
Left Ventricular Ejection ◽  
Angiotensin Ii Receptors ◽  
Angiotensin Ii Receptor ◽  
Cardiac Pathology ◽  
Receptor Blockers

Literature review on the use of angiotensin II receptors blockers in patients with combined pathology of the cardiovascular and renal systems: chronic heart failure and chronic kidney disease is presented. The angiotensin II receptors blockers positive effect is determined by the selective and complete type 1 receptors blockade and simultaneous stimulation of the type 2 receptors. On the one hand angiotensin II blockers are well-studied and widely used class of drugs in patients with cardiac pathology. On the other hand, the efficacy and safety of this drugs group in patients with renal impairment due to cardiac pathology or coexisting urinary system diseases are not well studied. Clinical studies have confirmed the angiotensin II receptor blockers pharmacotherapeutic activity and safety in reducing the cardiovascular events rate, including cardiovascular mortality, myocardial infarction, stroke, number of hospitalizations due to decompensated heart failure. There is data regarding the heart failure poor prognosis in decreased kidney function, but most of these studies were conducted in patients with end-stage renal failure. Data on angiotensin II receptor blockers effect on the course and prognosis of patients with heart failure in association with kidney damage is not enough. The effect of angiotensin II on the heart failure clinical presentation and outcomes according to the left ventricular ejection fraction preservation or reduction, and on the severity of kidney damage is not studied.

Abstract P150: Podocyte Derived Urinary Microparticles Are Elevated in Angiotensin II Induced Hypertension

Hypertension ◽  
2015 ◽  
Vol 66 (suppl_1) ◽  
Author(s):  
Uta Erdbruegger ◽  
Christine Rudy ◽  
Deric Bennett ◽  
Sylvia Cechova ◽  
Fang Chang ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Organ Damage ◽  
Kidney Damage ◽  
Parent Cell ◽  
Glomerular Injury ◽  
Non Invasive ◽  
Potential Marker ◽  
Induced Hypertension ◽  
Patients At Risk ◽  
Novel Biomarkers

Background: Early and non-invasive biomarkers of kidney damage are needed to identify hypertensive patients at risk for kidney damage. Urinary micropaticles (UMPs) have gained significant attention as potential novel biomarkers for kidney damage, and have already been identified in pre-albuminuric diabetic glomerular injury. These vesicles are less than 1 micron in size and carry markers of the parent cell. We hypothesized that podocyte derived UMPs are elevated in angiotensin II-induced hypertension (HTN) Methods: Primary podocytes were isolated and grown in culture. Wild-type mice were treated with AII (400ng/kg/min) via mini-osmotic pumps. Untreated WT mice served as controls. 24 hour urines were collected after 5 days of AII treatment. Enumeration and phenotyping of MPs was done of podocyte culture supernatant and urine. Podocalyxin (Pcal), podoplanin (Ppla) and annexin 5 (AV) were used as surface markers. Result: Pcal and Ppla positive MPs as well as AV positive and negative MPs were detectable in supernatant from primary podocyte cultures. Compared to untreated controls (n=3), AII treated mice (n=2) had an increase in systolic blood pressure (SBP) by 33 mmHG (p=0.02). Despite similar urinary albumin/creatinine ratios between groups, there was a trend of higher levels of total numbers of Ppla and Pcal positive MPs in hypertensive mice compared to untreated (Figure 1). In addition, Annexin negative but Ppla and Pcal positive MPs were also numerically higher in hypertensive mice. In conclusion, podocyte derived UMPs are detectable in AII HTN. These findings need to be confirmed in a larger group of animals. UMPs can be potential marker for kidney end-organ damage in HTN.

Activator protein-1 is necessary for angiotensin-II stimulation of human adrenocorticotropin receptor gene transcription

2001 ◽  
Vol 268 (6) ◽  
pp. 1802-1810
Author(s):  
Danielle Naville ◽  
Estelle Bordet ◽  
Marie-Claude Berthelon ◽  
Philippe Durand ◽  
Martine Begeot
Keyword(s):  
Angiotensin Ii ◽  
Gene Transcription ◽  
Receptor Gene ◽  
Activator Protein 1 ◽  
Activator Protein ◽  
Stimulation Of
Sign in / Sign up

Export Citation Format

Share Document